10-K: VivoSim Labs Pivots to 3D Human Tissue Services, Secures $10M from Eli Lilly and Addresses Nasdaq Listing Concerns

VivoSim Labs, Inc. has strategically shifted its business focus to providing 3D human tissue models for drug testing, securing an initial $10 million from Eli Lilly for its former FXR program, while successfully regaining compliance with Nasdaq listing requirements.

Summary

• VivoSim Labs, Inc. (formerly Organovo Holdings, Inc.) has transitioned from a clinical-stage biotechnology company focused on IBD drug development to a pharmaceutical and biotechnology services company.
• The company now specializes in providing testing of drugs and drug candidates using three-dimensional (3D) human tissue models of liver and intestine, known as New Approach Methodologies (NAM) models.
• On March 25, 2025, VivoSim Labs sold its FXR program and related assets to Eli Lilly and Company for an upfront cash payment of $10.0 million ($9.0 million at closing, $1.0 million in escrow for 15 months), with potential future milestone payments of up to $50.0 million.
• Effective April 24, 2025, the company changed its corporate name to VivoSim Labs, Inc. to reflect its new business model and leverage its existing intellectual property in 3D bioprinting.
• The company's liver toxicology platform demonstrated a best-in-class predictive power with 87.5% sensitivity (correctly identifying liver-toxic drugs) and 100% specificity (no false positives) in findings presented at the May 2025 Digestive Disease Week scientific conference.
• For the fiscal year ended March 31, 2025, the company reported a net loss of $2.488 million, a significant improvement from a net loss of $14.671 million in the prior fiscal year.
• Cash and cash equivalents increased to approximately $11.3 million as of March 31, 2025, from $2.9 million as of March 31, 2024, primarily due to the FXR program sale and financing activities.
• Operating losses decreased to $12.6 million for the year ended March 31, 2025, from $15.1 million for the year ended March 31, 2024.
• The company successfully regained compliance with Nasdaq's minimum bid price and stockholders' equity requirements by April 30, 2025, following a 1-for-12 reverse stock split effected on March 21, 2025, but remains under a one-year Mandatory Panel Monitor.
• Management and the independent registered public accounting firm have expressed substantial doubt about the company's ability to continue as a going concern without additional financing.
• As of March 31, 2025, the company had 539,060 outstanding warrants to purchase common stock at an exercise price of $9.60 per share, expiring on May 13, 2029.

Sentiment

Score: 4

Explanation: While the company has made positive strides in reducing losses, increasing cash, and regaining Nasdaq compliance, the explicit 'substantial doubt about its ability to continue as a going concern' and the unproven nature of its new business model present significant fundamental risks. The reliance on future capital raises in a challenging market context weighs heavily on the sentiment, despite the promising early data from its new platform.

Positives

• Successful sale of the FXR program to Eli Lilly and Company for an upfront payment of $10.0 million, with potential for up to $50.0 million in future milestone payments.
• Significant improvement in net loss, decreasing to $2.488 million for FY2025 from $14.671 million for FY2024.
• Increase in cash and cash equivalents to $11.3 million as of March 31, 2025, from $2.9 million in the prior year, enhancing liquidity.
• Reduction in operating losses and negative cash flows from operations, indicating improved operational efficiency.
• Successful regaining of compliance with Nasdaq listing requirements (minimum bid price and stockholders' equity) by April 30, 2025, maintaining its listing on the Nasdaq Capital Market.
• Liver toxicology platform demonstrated 'best-in-class predictive power' with 87.5% sensitivity and 100% specificity, a 'worlds best' for sensitivity, which could attract pharmaceutical partners.
• Strategic pivot to a services-based model aligns with anticipated accelerated adoption of human tissue models following the U.S. FDA's April 10, 2025 announcement favoring non-animal NAM methods.

Negatives

• Management and independent auditors have concluded that substantial doubt exists about the company's ability to continue as a going concern without additional capital.
• The company has a history of recurring operating losses and expects to incur significant additional operating losses in the foreseeable future.
• Reliance on future funding through equity offerings, debt financings, or collaboration arrangements, with no committed external source of funds.
• The public float of common stock is less than $75.0 million, limiting the amount of capital that can be raised through primary public offerings to one-third of the public float in any twelve-month period.
• The new business strategy of providing 3D human tissue models for drug testing is described as 'new and unproven', with no drug candidates identified or developed using this model to date.
• The company faces intense competition from major drug companies, specialized biotechnology firms, academic institutions, and government agencies, many with significantly greater resources.
• An ongoing legal proceeding with H.C. Wainwright & Co., LLC, alleging breach of a tail financing provision, could result in substantial costs and diversion of management attention.
• The Mosaic Cell Sciences division, intended to be a profit center, ended commercial operations in Q3 FY2025 due to not achieving significant revenues as expected.

Risks

• Substantial additional operating losses are expected over the next several years as services and R&D activities proceed, with uncertain timelines for profitability.
• The business strategy of using platform technology to develop human tissues and disease models for drug discovery and development is new and unproven, potentially leading to unforeseen technical complications or delays.
• Intense competition in the biotechnology and pharmaceutical industry from entities with significantly greater financial and technical resources.
• Requirement for a constant, steady, reliable supply of human cells, with no guarantee of cost-effective access to the necessary quantity and quality of raw materials.
• Need for substantial additional funding, which if not available on acceptable terms or at all, could lead to curtailment or cessation of operations and significant dilution to existing stockholders.
• Clinical drug development, which the company will support for third parties and pursue internally, is a lengthy, expensive process with uncertain outcomes, and earlier results may not be predictive of future results.
• Reliance on third-party contractors and service providers for critical aspects of development programs, with risks of delays, quality issues, or financial distress of these parties.
• The near and long-term viability of the services platform and R&D efforts depend on successfully establishing strategic relationships, which is difficult and time-consuming.
• Current and future legislation, including healthcare reform measures and drug pricing scrutiny, may increase the difficulty and cost of commercializing drug candidates and affect prices.
• Unstable market and economic conditions could adversely affect business, financial condition, and share price, including the ability to raise capital.
• Risk of security breaches or other cybersecurity incidents compromising information and exposing the company to liability, with evolving global privacy and data security requirements.
• Potential conflicts of interest with Viscient Biosciences, Inc., due to shared executive leadership and business dealings, which may not always be resolved in the company's favor.
• Failure to maintain Nasdaq listing could seriously harm stock liquidity and ability to raise capital or complete strategic transactions.
• The price of common stock may continue to be volatile, leading to investor losses and potential costly securities litigation.
• Future issuance of additional shares of capital stock could cause substantial dilution to existing stockholders and downward pressure on the stock price.
• Patents covering products could be found invalid or unenforceable if challenged, and the company may be involved in expensive and time-consuming lawsuits to protect intellectual property.
• Changes in U.S. patent law or foreign patent law could diminish the value of patents, impairing the ability to protect products.
• Dependence on license agreements with the University of Missouri, with failure to comply or termination potentially harming the business.

Future Outlook

VivoSim Labs intends to focus on providing liver and intestinal toxicology insights using NAM models to pharmaceutical and biotech companies, aiming to reduce drug development risk and cost. The company anticipates accelerated adoption of human tissue models following the FDA's announcement favoring non-animal NAM methods. However, the company will need substantial additional funding to support future operating activities, with expected total operating expenses of approximately $10.1 million for the fiscal year ending March 31, 2026.

Management Comments

• "We anticipate accelerated adoption of human tissue models following the U.S. Food and Drug Administration ('FDA') announcement on April 10, 2025 to refine animal testing requirements in favor of these non-animal NAM methods."
• "We changed our name to reflect our new business model, which includes the use of other longstanding assets of the Company, intestinal and liver tox models and expertise, and our IP portfolio for 3D bioprinting."
• "Our services offer the potential benefit of reducing the significant risk and cost of bringing therapeutics to market through the regulatory process."
• "Our liver predictive power was shown to be 87.5% for a set of challenging liver toxicity cases... This is known as the sensitivity of the platform, which at 87.5% is a worlds best. Importantly, the specificity was 100%, meaning that none of the compounds tested that are not liver toxic were incorrectly identified as having liver toxicity issues by the platform."
• "We presently intend to retain all earnings, if any, and accordingly our board of directors does not anticipate declaring any dividends prior to a business combination."
• "Management has performed an analysis and concluded that substantial doubt exists about our ability to continue as a going concern."

Industry Context

The company's strategic pivot to providing 3D human tissue models for drug testing aligns with a broader industry trend towards New Approach Methodologies (NAMs), particularly reinforced by the U.S. FDA's April 10, 2025 announcement favoring non-animal testing requirements. This shift aims to address the high failure rates and costs in traditional drug development, where a significant portion of drug candidates fail due to unexpected liver toxicity or intestinal intolerability. The company positions itself to capitalize on the increasing demand for more predictive and cost-effective preclinical testing methods.

Comparison to Industry Standards

• VivoSim Labs' liver toxicology platform demonstrated 'best-in-class predictive power' with 87.5% sensitivity for identifying known liver-toxic drugs, which the company states is a 'worlds best' sensitivity.
• The platform also achieved 100% specificity, meaning no non-liver-toxic compounds were incorrectly identified as toxic, which is a strong indicator of reliability in the industry.
• While the document highlights these strong performance metrics, it does not provide specific comparable companies or projects by name for direct benchmarking.

Management Changes

Corporate Governance

Legal Proceedings

• H.C. Wainwright & Co., LLC filed a complaint on August 27, 2024, in the Supreme Court of the State of New York, alleging breach of a tail financing provision in a May 2023 engagement agreement.
• H.C. Wainwright is seeking compensatory and consequential damages and attorneys' fees.
• The company filed an answer to the complaint on October 18, 2024, and is vigorously defending the claims.
• An accrual of $0.6 million has been recorded for loss contingencies associated with this complaint, with $0.4 million in accrued expenses and $0.2 million classified as a liability to be settled in equity.

Related Party Transactions

• The company has an intercompany agreement with Viscient Biosciences, Inc., where Keith Murphy (VivoSim's Executive Chairman) also serves as CEO and principal stockholder of Viscient.
• Under this agreement, VivoSim provides Viscient with 3D bioprinting technology services (e.g., histology, cell isolation) and Viscient provides VivoSim with services (e.g., bioprinter training, qPCR assays).
• In fiscal year 2025, VivoSim incurred $118,000 in R&D consulting expenses from Viscient and provided approximately $3,000 of histology services to Viscient.
• Certain VivoSim board members (Adam Stern, Douglas Jay Cohen, David Gobel) have invested in Viscient through a convertible promissory note.

Stakeholder Impact

• **Shareholders:** Face potential dilution from future equity offerings, continued stock price volatility, and the risk associated with the 'going concern' warning. The reverse stock split and Nasdaq compliance efforts aim to protect listing, but the Mandatory Panel Monitor indicates ongoing scrutiny.
• **Employees:** Experienced a workforce reduction of approximately 24% in August 2023, impacting job security for some. Equity incentive plans are in place to attract and retain key personnel, but the company's financial stability remains a concern.
• **Customers (Pharmaceutical/Biotech Companies):** Will benefit from the company's new focus on providing 3D human tissue models for drug testing, potentially reducing their R&D costs and risks. The 'best-in-class' liver toxicology platform could be a significant value proposition.
• **Suppliers:** The company's need for a constant, steady, reliable supply of human cells means continued business for selected third-party suppliers, but the company's financial health could impact payment terms or volume.
• **Creditors:** The 'going concern' warning indicates increased risk for current and potential creditors, as the company's ability to satisfy liabilities in the normal course of business is in doubt without additional financing.

Next Steps

• Secure substantial additional funding to support future operating activities and implement the new business plan.
• Continue to build out the services platform, focusing on liver and intestinal toxicology insights using NAM models.
• Pursue partnering arrangements with pharmaceutical companies for safety and toxicology assessment services.
• Advance internal research and development programs, validating targets, and testing external drug compounds for partnering or internal clinical development.
• Manage the one-year Mandatory Panel Monitor period by Nasdaq to maintain listing compliance.
• Continue to defend against the H.C. Wainwright & Co., LLC legal complaint.

Key Dates

Recommendation

Keywords

3D human tissue models, drug testing services, liver toxicology, intestinal toxicology, NAM models, biotechnology services, pharmaceutical services, drug discovery, preclinical testing, bioprinting, intellectual property, Nasdaq compliance, going concern, Eli Lilly, FXR program, VIVS